PLX4032 (Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors.
Biotool LLC
聯系商家時請?zhí)峒癱hemicalbook，有助于交易順利完成！